The biopharmaceutical company manufactures medicines for Alzheimer’s, dementia, psychiatric disorders, cardiovascular, diabetes, oncology, and hepatitis.
Looking for leads, investment insights, or competitive intelligence?
News about Bristol-Myers Squibb
Celgene boosted the price of a 10-milligram dose of Revlimid by 3.5% to $719.82 effective Jan. 3.
Must-read business news, delivered every morning.
It's one of the largest pharmaceutical-company mergers ever.
Russian drugmaker Nativa got a compulsory license to produce a cheaper version of Celgene's Revlimid.
Chinese drug regulators gave the nod to Bristol-Myers Squibb’s immune therapy star Opdivo. Dozens of companies are hoping they’re next.